Zhongzhi Pharmaceutical Holdings Limited released its Monthly Return for the period ended 30 September 2026, confirming that both authorised and issued share capital remained unchanged.

The company’s authorised share capital stands at 1.56 billion ordinary shares with a par value of HKD 0.01 each, equivalent to HKD 15.60 million. Issued shares total 863.60 million, with zero treasury shares outstanding.

Throughout September 2026, Zhongzhi Pharmaceutical recorded: • No increase or decrease in authorised or issued shares. • No share options, warrants, convertibles, or other equity-linked instruments issued, exercised, or outstanding. • No share repurchases, cancellations, or treasury share transactions.

Management also confirmed that the company continued to meet the Hong Kong Stock Exchange’s minimum public-float requirement of 25 percent of issued shares as at month-end.

The monthly return was submitted to Hong Kong Exchanges and Clearing Limited on 2 October 2026 and signed by Director Lai Zhi Tian, affirming compliance with all relevant listing rules and regulatory obligations.